Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

44.34 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,864
Open 44.34
Bid (Size) 44.15 (2)
Ask (Size) 44.28 (3)
Prev. Close 44.34
Today's Range 44.34 - 44.34
52wk Range 41.45 - 56.32
Shares Outstanding 5,606,688,356
Dividend Yield 3.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Got $1,000? 3 Cheap Stocks To Buy Right Now
We may be entering a period of prolonged leadership from undervalued stocks, with these tickers poised to lead the charge. 
Via The Motley Fool

Performance

YTD
-13.50%
-13.50%
1 Month
-13.50%
-13.50%
3 Month
-4.79%
-4.79%
6 Month
-11.07%
-11.07%
1 Year
-17.68%
-17.68%

More News

Read More
This Low-Risk ETF Can Turn $39,000 Into $1 Million in 25 Years
Via The Motley Fool
Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.
Via The Motley Fool
Novavax Shares Jumped in January While Others Slipped
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer (PFE) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Pfizer Beats Q4 Earnings, Issues Underwhelming 2023 Guidance
Via Benzinga
AMD To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Via MarketBeat
S&P 500 Jumps 1.5%, Market Volatility Decreases
Via Benzinga
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Via The Motley Fool
Dow Surges Over 200 Points; Pfizer Issues Weak Forecast
Via Benzinga
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Via Investor's Business Daily
Waiting for Powell: As Fed Meeting Starts, Investors Parse Mixed Q4 Earnings and Consider What's Next for Rates
Via Benzinga
Sony Scales Back PlayStation VR2 Output, Sam Bankman-Fried Attempted To Regain Control Of FTX, White House Plans To End COVID-19 Emergency: Today's Top Stories
Via Benzinga
Why BioNTech And Moderna Shares Are Falling After Pfizer News
Via Benzinga
Most Important Week Of Earnings Season Is Here — Will S&P 500 Companies Continue Beating Wall Street Estimates?
Via Benzinga
Pfizer Q4 Earnings And Revenues Beat Estimates
Via Talk Markets
The Expected Covid Cliff Is Here For Pfizer — Company Calls For Steep 2023 Declines
Via Investor's Business Daily
Biden Administration Plans To End COVID-19 Public Health Emergency In May
Via Benzinga
4 Discounted Dividend Stocks To Buy In February 2023
Via The Motley Fool
These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts
Via Benzinga
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
From Pfizer Inc.
Via Business Wire
Nasdaq, S&P Futures Lower As Powell & Team Kick Off 2-Day Fed Meeting: Analyst Says Positive January Harbinger Of Good Times
Via Benzinga
Earnings Scheduled For January 31, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.